| scholarly article | Q13442814 |
| P2093 | author name string | Keith A Josephs | |
| P2860 | cites work | Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy | Q62066110 |
| Molecular flexibility in microtubule proteins: proton nuclear magnetic resonance characterization | Q71759873 | ||
| Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype | Q74096757 | ||
| Alien Hand Syndrome | Q87692599 | ||
| A protein factor essential for microtubule assembly | Q22010837 | ||
| Classification of primary progressive aphasia and its variants | Q24594803 | ||
| Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia | Q24598142 | ||
| Characterizing a neurodegenerative syndrome: primary progressive apraxia of speech | Q24632112 | ||
| Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau | Q24648590 | ||
| Transmission and spreading of tauopathy in transgenic mouse brain | Q24651334 | ||
| Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study | Q24655620 | ||
| Familial multiple system tauopathy with presenile dementia: a disease with abundant neuronal and glial tau filaments | Q24684804 | ||
| Neuropathological stageing of Alzheimer-related changes | Q27860862 | ||
| The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy | Q28085165 | ||
| Tau binds to the distal axon early in development of polarity in a microtubule- and microfilament-dependent manner | Q28568174 | ||
| Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease | Q28910345 | ||
| Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B | Q29012704 | ||
| Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy | Q29417026 | ||
| Novel proteinaceous infectious particles cause scrapie | Q29547678 | ||
| Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium | Q29614409 | ||
| Syndromes dominated by apraxia of speech show distinct characteristics from agrammatic PPA. | Q30544788 | ||
| Functional implications for the microtubule-associated protein tau: localization in oligodendrocytes | Q33838732 | ||
| The Selective Impairment of Semantic Memory | Q33958799 | ||
| Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial | Q34031302 | ||
| Identification of cDNA clones for the human microtubule-associated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein 2. | Q34166092 | ||
| Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism | Q34405999 | ||
| Primary age-related tauopathy (PART): a common pathology associated with human aging | Q34445021 | ||
| What does it mean to be natively unfolded? | Q34488954 | ||
| The evolution of primary progressive apraxia of speech | Q34500103 | ||
| Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). | Q34550595 | ||
| National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease | Q34635272 | ||
| Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity | Q34695519 | ||
| Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome | Q35540064 | ||
| Tau positron emission tomographic imaging in aging and early Alzheimer disease | Q36535275 | ||
| Criteria for the diagnosis of corticobasal degeneration | Q36661843 | ||
| Tau imaging in neurodegenerative diseases | Q36834567 | ||
| Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue | Q36987267 | ||
| An autoradiographic evaluation of AV-1451 Tau PET in dementia | Q37001820 | ||
| Midbrain atrophy is not a biomarker of progressive supranuclear palsy pathology | Q37170598 | ||
| Prion-like mechanisms in neurodegenerative diseases | Q37661351 | ||
| Neuropathological background of phenotypical variability in frontotemporal dementia | Q37879961 | ||
| Invited review: Prion-like transmission and spreading of tau pathology | Q38268519 | ||
| Tau immunotherapy for Alzheimer's disease | Q38407801 | ||
| Does corticobasal degeneration exist? A clinicopathological re-evaluation | Q38415885 | ||
| Effectiveness of allied health therapy in the symptomatic management of progressive supranuclear palsy: a systematic review | Q38929702 | ||
| Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. | Q39021126 | ||
| The L266V tau mutation is associated with frontotemporal dementia and Pick-like 3R and 4R tauopathy | Q39071728 | ||
| Argyrophilic grain disease is a sporadic 4-repeat tauopathy | Q39527344 | ||
| Propagation of tau misfolding from the outside to the inside of a cell. | Q39873721 | ||
| Haplotype-specific expression of the N-terminal exons 2 and 3 at the human MAPT locus | Q40113301 | ||
| The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts | Q40194429 | ||
| [18 F]AV-1451 tau positron emission tomography in progressive supranuclear palsy | Q41350096 | ||
| Distinct tau prion strains propagate in cells and mice and define different tauopathies | Q41904960 | ||
| Tau and tauopathies. | Q42498793 | ||
| Tau imaging with [18 F]THK-5351 in progressive supranuclear palsy | Q42501180 | ||
| Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias | Q42699490 | ||
| [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease | Q42712929 | ||
| Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. | Q45810537 | ||
| Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice | Q46533399 | ||
| Association of an extended haplotype in the tau gene with progressive supranuclear palsy | Q47726308 | ||
| Microtubule-associated protein tau, heparan sulphate and alpha-synuclein in several neurodegenerative diseases with dementia | Q48180540 | ||
| Phosphorylated serine422 on tau proteins is a pathological epitope found in several diseases with neurofibrillary degeneration | Q48255703 | ||
| Phosphorylation determines two distinct species of Tau in the central nervous system | Q48261881 | ||
| Atrophy of superior cerebellar peduncle in progressive supranuclear palsy. | Q48286229 | ||
| Photophobia, visual hallucinations, and REM sleep behavior disorder in progressive supranuclear palsy and corticobasal degeneration: a prospective study | Q48440558 | ||
| Increased basal ganglia binding of 18 F-AV-1451 in patients with progressive supranuclear palsy | Q48486327 | ||
| [18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration | Q48505309 | ||
| Vulnerable neuronal subsets in Alzheimer's and Pick's disease are distinguished by their tau isoform distribution and phosphorylation. | Q48521878 | ||
| Penguins and hummingbirds: midbrain atrophy in progressive supranuclear palsy | Q48602878 | ||
| Tau PET in Alzheimer disease and mild cognitive impairment. | Q48648902 | ||
| Phosphorylation affects the ability of tau protein to promote microtubule assembly. | Q48681817 | ||
| Tau propagation, different tau phenotypes, and prion-like properties of tau. | Q48707817 | ||
| Magnetic resonance imaging signatures of tissue pathology in frontotemporal dementia | Q48770348 | ||
| New and reliable MRI diagnosis for progressive supranuclear palsy | Q48830253 | ||
| The pimple sign of progressive supranuclear palsy syndrome | Q48861557 | ||
| Quantitative MRI measurement of superior cerebellar peduncle in progressive supranuclear palsy | Q49023425 | ||
| A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. | Q50479057 | ||
| The natively unfolded character of tau and its aggregation to Alzheimer-like paired helical filaments. | Q52589143 | ||
| FDG-PET in pathologically confirmed spontaneous 4R-tauopathy variants. | Q53080836 | ||
| Pattern of Tau forms in CSF is altered in progressive supranuclear palsy. | Q53288614 | ||
| Elevated in vivo [18F]-AV-1451 uptake in a patient with progressive supranuclear palsy. | Q54737738 | ||
| High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy | Q57306388 | ||
| Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy | Q57384519 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | neurodegeneration | Q1755122 |
| P304 | page(s) | 1291-1303 | |
| P577 | publication date | 2017-08-01 | |
| P1433 | published in | Mayo Clin Proc | Q6538184 |
| P1476 | title | Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau. | |
| P478 | volume | 92 |
| Q92156047 | Current Progress of Research on Neurodegenerative Diseases of Salvianolic Acid B |
| Q64076343 | Serum and cerebrospinal fluid tau protein level as biomarkers for evaluating acute spinal cord injury severity and motor function outcome |
| Q88990567 | Spatial Patterns of Hypometabolism and Amyloid Deposition in Variants of Alzheimer's Disease Corresponding to Brain Networks: a Prospective Cohort Study |
| Q64956774 | Tau Imaging in Neurodegenerative Diseases Using Positron Emission Tomography. |
| Q57838382 | Transcellular Spreading of Tau in Tauopathies |
Search more.